Sanai Toru, Nanishi Fumio, Nagata Masatoshi, Hirano Tadashi, Suematsu Eiichi, Esaki Yukio, Miyahara Hisaaki, Iida Mitsuo
The Division of Nephrology and Rheumatology, Clinical Research Institute, National Kyushu Medical Center, Fukuoka, Japan.
Rheumatol Int. 2007 Feb;27(4):363-7. doi: 10.1007/s00296-006-0225-1. Epub 2006 Sep 30.
The role of secondary amyloidosis in determining the prognosis of dialyzed patients with rheumatoid arthritis (RA) was examined in 22 patients with a mean age of 60.1 years included 21 renal amyloidosis. RA duration until the start of dialysis was 19.5 +/- 7.2 years and the observation period after introduction 27.1 +/- 26.4 months. Of the 14 dead cases, four died due to sepsis, three due to gastrointestinal tract bleeding, two due to congestive heart failure, and eight cases died within 5 months after starting dialysis. When comparing the eight survivors and the nine non-survivors who died within 2 years after the start of dialysis, the former patients showed significantly higher serum albumin, and lower electrocardiogram score and cardiothoracic ratios at the time of introduction to dialysis. The careful prevention and treatment of infection, cerebrovascular and/or gastrointestinal tract complications seem to be necessary to improve the prognosis of RA patients after the initiation of renal replacement therapy.
对22例平均年龄60.1岁的患者进行了研究,以探讨继发性淀粉样变性在确定类风湿关节炎(RA)透析患者预后中的作用,其中包括21例肾淀粉样变性患者。开始透析前的RA病程为19.5±7.2年,开始透析后的观察期为27.1±26.4个月。在14例死亡病例中,4例死于败血症,3例死于胃肠道出血,2例死于充血性心力衰竭,8例在开始透析后5个月内死亡。比较开始透析后2年内死亡的8例幸存者和9例非幸存者,前者在开始透析时血清白蛋白显著更高,心电图评分和心胸比率更低。对于接受肾脏替代治疗后的RA患者,似乎有必要仔细预防和治疗感染、脑血管和/或胃肠道并发症,以改善其预后。